X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (956) 956
oncology (910) 910
radiation-therapy (718) 718
therapy-oncology-group (642) 642
radiotherapy (625) 625
male (535) 535
middle aged (516) 516
female (507) 507
therapy oncology group (496) 496
aged (482) 482
adult (383) 383
radiology, nuclear medicine & medical imaging (351) 351
combined modality therapy (320) 320
index medicus (305) 305
chemotherapy (301) 301
brain neoplasms - secondary (257) 257
carcinoma (257) 257
cancer (244) 244
radiotherapy dosage (242) 242
treatment outcome (242) 242
survival (226) 226
aged, 80 and over (224) 224
lung neoplasms - radiotherapy (217) 217
prognosis (204) 204
surgery (200) 200
carcinoma, non-small-cell lung - radiotherapy (197) 197
lung neoplasms - pathology (197) 197
retrospective studies (190) 190
brain neoplasms - radiotherapy (184) 184
survival analysis (183) 183
randomized trial (177) 177
neoplasm staging (169) 169
survival rate (168) 168
irradiation (166) 166
care and treatment (164) 164
brain metastases (158) 158
trial (150) 150
radiosurgery (147) 147
radiation (143) 143
randomized-trial (140) 140
hematology, oncology and palliative medicine (133) 133
carcinoma, non-small-cell lung - pathology (131) 131
lung cancer (127) 127
brain neoplasms - surgery (126) 126
stereotactic radiosurgery (124) 124
antineoplastic combined chemotherapy protocols - therapeutic use (119) 119
lung neoplasms - drug therapy (117) 117
follow-up studies (115) 115
radiation therapy (113) 113
metastasis (112) 112
carcinoma, non-small-cell lung - drug therapy (111) 111
cisplatin (109) 109
clinical neurology (109) 109
cell lung-cancer (107) 107
brain neoplasms - mortality (105) 105
dose fractionation (102) 102
cerebral metastases (100) 100
antineoplastic agents - therapeutic use (94) 94
prognostic factors (93) 93
disease-free survival (92) 92
phase-iii trial (84) 84
lung cancer, non-small cell (80) 80
prognostic-factors (80) 80
time factors (78) 78
management (77) 77
prospective studies (77) 77
multivariate analysis (76) 76
radiology (76) 76
chemotherapy, adjuvant (75) 75
toxicity (75) 75
palliation (74) 74
lung neoplasms - mortality (72) 72
phase-iii (72) 72
tumors (72) 72
cisplatin - administration & dosage (68) 68
research (68) 68
respiratory system (68) 68
analysis (66) 66
phase-ii (66) 66
quality of life (66) 66
radiology and nuclear medicine (66) 66
carcinoma, non-small-cell lung - mortality (65) 65
dose-response relationship, radiation (65) 65
lung neoplasms - therapy (65) 65
palliative care (65) 65
carcinoma, squamous cell - radiotherapy (64) 64
brain neoplasms - therapy (63) 63
clinical trials as topic (63) 63
medicine & public health (63) 63
squamous-cell carcinoma (63) 63
quality-of-life (62) 62
non-small cell lung cancer (60) 60
patients (59) 59
recursive partitioning analysis (59) 59
concurrent chemotherapy (58) 58
cranial irradiation (58) 58
radiosurgery - methods (58) 58
carcinoma, non-small-cell lung - therapy (57) 57
prophylactic cranial irradiation (56) 56
randomized controlled trials as topic (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1147) 1147
French (28) 28
German (15) 15
Chinese (4) 4
Spanish (4) 4
Japanese (3) 3
Italian (1) 1
Polish (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 187 - 199
Summary Background We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | COMPETING RISK | CLINICAL-TRIALS | THERAPY ONCOLOGY GROUP | CHEMORADIATION | INDUCTION | CARCINOMA | CHEMOTHERAPY | RADIATION-THERAPY | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Radiotherapy, Image-Guided | Chemoradiotherapy | Carcinoma, Large Cell - secondary | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Cetuximab | Paclitaxel - administration & dosage | Radiotherapy Dosage | Carboplatin - administration & dosage | Carcinoma, Squamous Cell - therapy | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Radiotherapy, Conformal | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Chemotherapy | Dosage and administration | Lung cancer, Non-small cell | Antineoplastic agents | Radiotherapy | Cancer | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10055, pp. 2004 - 2014
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2011, Volume 103, Issue 19, pp. 1452 - 1460
Background The combination of chemotherapy with thoracic radiotherapy (TRT) compared with TRT alone has been shown to confer a survival advantage for good... 
IRRADIATION | CARBOPLATIN | CISPLATIN | VINORELBINE | ONCOLOGY | THERAPY-ONCOLOGY-GROUP | CHEMORADIOTHERAPY | RADIOTHERAPY | CHEMOTHERAPY | RADIATION-THERAPY | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Time Factors | Vinblastine - adverse effects | Aged, 80 and over | Adult | Dose Fractionation | Chemotherapy, Adjuvant | Odds Ratio | Radiotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Etoposide - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Disease Progression | Canada | Confounding Factors (Epidemiology) | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Etoposide | Research | Lung cancer, Non-small cell | Drug therapy | Radiotherapy | Health aspects | Index Medicus
Journal Article
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ISSN 0360-3016, 02/2005, Volume 61, Issue 2, pp. 318 - 328
Purpose: To evaluate prospectively the acute and late morbidities from a multiinstitutional three-dimensional radiotherapy dose-escalation study for inoperable... 
SURVIVAL | CANCER NSCLC | dose-escalation trial | VOLUME | THERAPY ONCOLOGY GROUP | TUMORS | RADIATION-THERAPY | TRIAL | ONCOLOGY | PNEUMONITIS | RTOG | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | non-small-cell lung cancer
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 76, Issue 3, pp. S70 - S76
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9687, pp. 379 - 386
Journal Article
Journal of neurosurgery, ISSN 0022-3085, 01/2015, Volume 122, Issue 1, pp. 4 - 23
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 2, pp. 107 - 118
A course of androgen-deprivation therapy before and during radiotherapy prolonged 10-year survival by about 7% among men with intermediate-risk prostate... 
MEDICINE, GENERAL & INTERNAL | EXTERNAL-BEAM RADIOTHERAPY | THERAPY ONCOLOGY GROUP | DOSE-ESCALATION TRIAL | FOLLOW-UP | RADICAL PROSTATECTOMY | RANDOMIZED CONTROLLED-TRIAL | SUPPRESSION | HORMONAL-THERAPY | GROUP RTOG | RADIATION-THERAPY | Multivariate Analysis | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Risk | Radiotherapy - adverse effects | Flutamide - adverse effects | Prostate - pathology | Leuprolide - administration & dosage | Aged, 80 and over | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Radiotherapy Dosage | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Survival Rate | Combined Modality Therapy | Erectile Dysfunction - etiology | Prostatic Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Leuprolide - adverse effects | Aged | Flutamide - administration & dosage | Androgen Antagonists - adverse effects | Usage | Care and treatment | Hormone therapy | Diagnosis | Radiotherapy | Health aspects | Prostate cancer | Adenocarcinoma | Short term | Lymphatic system | Risk groups | Prostate-specific antigen | Mortality | Blood tests | Oncology | Metastasis | Radiation therapy | Phosphatase | Cancer therapies | Survival | Metastases | Androgens | Biopsy | Surgery | Prostate | Tumors | Index Medicus | Abridged Index Medicus